Allergan may sell faltering obesity unit; Takeda's lymphoma drug Adcetris wins EU nod;

@FiercePharma: BMJ says no more clinical trial publications if actual data isn't open for outside review. More | Follow @FiercePharma

> Allergan ($AGN) is mulling the sale of its obesity business after Lap-Band sales dropped 21% for the third quarter; the company's profits managed to beat expectations on a 6% rise in overall sales. Report

> AstraZeneca ($AZN) says it will relax restrictions on employee travel and partipation in industry conferences. Report

> European regulators granted conditional approval to Takeda Pharmaceutical's non-Hodgkin lymphoma drug Adcetris, recently launched in the U.S. Report

> Stringent austerity measures will deliver a 15% savings in Spain's drug spending, which, together with unpaid pharma bills, has pushed the industry to "the brink of collapse," Farmaindustria says. Report

> Roche's ($RHHBY) Avastin won a new ovarian cancer indication from European regulators. Report

> The European Medicines Agency expanded use of Eli Lilly's ($LLY) erectile dysfunction drug Cialis to patients with enlarged-prostate symptoms. Report

> Poland's pharma market will lose steam this year, as new pricing policies send growth into negative territory. Report

> U.S. Centers for Disease Control and Prevention added three to the death toll in the ongoing meningitis outbreak linked to compounded drugs; it's now 28. Report

Medical Device News

 @FierceMedDev: Boston Sci snagged EU approval for its new stent with bioabsorbable coating. News | Follow @FierceMedDev

 @MarkHFierce: Fidelity is investing $75M into Trivitron Healthcare, an Indian company focused on imaging and lab Dx. Release | Follow @MarkHFierce

 @DamianFierce: The latest Cleveland Clinic top 10 innovations list includes some novel medical devices. Article | Follow @DamianFierce

> GI Dynamics moves toward FDA approval for weight-loss tech. Story

> OptiScan, maker of glucose monitoring devices, raises $2.6M. Item

Biotech News

 @FierceBiotech: Ipsen braces for $153M write-off as troubled biotech partner declares bankruptcy. News | Follow @FierceBiotech

 @JohnCFierce: Biocon (India) scouts R&D pact after GE unit grabs stake in research division. Story | Follow @JohnCFierce

 @RyanMFierce: Biotech's boneyard: 2012 report on the dead, dying, disabled (and some reborn) biotech operations. Happy Halloween! Special Report | Follow @RyanMFierce

> Researchers nab $11M to fund second look at AstraZeneca's stockpile of failed drugs. Article

> Biogen streak lives on with upbeat PhIII results for hemophilia A therapy. Story

Drug Delivery News

> Twice-yearly opioid dependence implant steps closer to the market. Item

> Ocular Therapeutix eyes up positive results for OTX-TP2. Article

> Starpharma technology delivers 40-fold more docetaxel to tumor. Report

> Paclitaxel particles extend life threefold in mouse bladder cancer. News

Biomarkers News

> Seeing is believing: Biomarkers visible to the naked eye. Item

> Blood biomarker tags NeuVax's role in breast cancer treatment. Article

> Marking glimpses of activity for Lilly's Alzheimer drug after PhIII struggles. Report

> U.K. researchers spot new marker for prostate cancer prognosis. News

> Chromosome cap length predicts pancreatic cancer risk. Story

And Finally... Diabetes rates are soaring in Saudi Arabia as the government is pledging billions to improve healthcare. Report

 

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.